GlassScriptPhysician profile
Amy Doyon
NPI 1336818186
$5,340.61
in general payments reported to CMS, 2019-2025
23 companies · $1,170 in 2025
The $1,170 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.77 · 2022: $706 · 2023: $1,955 · 2024: $1,467 · 2025: $1,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,301 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,300.87 |
| Education | $290.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,322.79 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $552.21 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $500.91 | 2022-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $335.66 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $331.64 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $317.11 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $302.04 | 2022-2025 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $283.66 | 2024-2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $223.50 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $209.21 | 2023-2025 | Auvelity |
| Corium, LLC | $166.98 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $135.59 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $117.54 | 2023-2025 | Secuado, Xelstrym |
| Indivior INC. | $115.02 | 2022-2024 | Perseris, Sublocade |
| Ironshore Pharmaceuticals INC. | $99.58 | 2023-2024 | Jornay Pm |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $62.64 | 2023-2025 | Rexulti |
| Almatica Pharma LLC | $60.85 | 2023-2025 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $60.63 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $56.84 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $25.65 | 2022 | |
| Owp Pharmaceuticals, INC. | $23.98 | 2023 | Lamotrigine, Subvenite |
| Exact Sciences Corporation | $18.90 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $17.68 | 2023 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Doyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.